OBJECTIVE: To inform guidelines concerning when to initiate combination antiretroviral therapy (ART), we investigated whether CD4(+) T-cell counts (CD4 cell counts) continue to increase over long periods of time on ART. Losses-to-follow-up and some patients discontinuing ART at higher CD4 cell counts hamper such evaluation, but novel statistical methods can help address these issues. We estimated the long-term CD4 cell count trajectory accounting for losses-to-follow-up and treatment discontinuations. DESIGN: The study population included 898 US patients first initiating ART in a randomized trial (AIDS Clinical Trials Group 384); 575 were subsequently prospectively followed in an observational study (AIDS Clinical Trials Group Longitudinal Linked Randomized Trials). METHODS: Inverse probability of censoring weighting statistical methods were used to estimate the CD4 cell count trajectory accounting for losses-to-follow-up and ART discontinuations, overall and for pretreatment CD4 cell count categories (<or=200, 201-350, 351-500, and >500 cells/microl). RESULTS:Median CD4 cell count increased from 270 cells/microl pre-ART to an estimated 556 cells/microl at 3 and 532 cells/microl at 7 years after starting ART in analyses ignoring treatment discontinuations, and to 570 and 640 cells/microl, respectively, had all patients continued ART. However, even had ART been continued, an estimated 25, 9, 3, and 2% of patients with pretreatment CD4 cell counts of 200 or less, 201-350, 351-500, and more than 500 cells/microl would have had CD4 cell counts of 350 cells/microl or less after 7 years. CONCLUSION: If patients remain on ART, CD4 cell counts increase in most patients for at least 7 years. However, the substantial percentage of patients starting therapy at low CD4 cell counts who still had low CD4 cell counts after 7 years provides support for ART initiation at higher CD4 cell counts.
RCT Entities:
OBJECTIVE: To inform guidelines concerning when to initiate combination antiretroviral therapy (ART), we investigated whether CD4(+) T-cell counts (CD4 cell counts) continue to increase over long periods of time on ART. Losses-to-follow-up and some patients discontinuing ART at higher CD4 cell counts hamper such evaluation, but novel statistical methods can help address these issues. We estimated the long-term CD4 cell count trajectory accounting for losses-to-follow-up and treatment discontinuations. DESIGN: The study population included 898 US patients first initiating ART in a randomized trial (AIDS Clinical Trials Group 384); 575 were subsequently prospectively followed in an observational study (AIDS Clinical Trials Group Longitudinal Linked Randomized Trials). METHODS: Inverse probability of censoring weighting statistical methods were used to estimate the CD4 cell count trajectory accounting for losses-to-follow-up and ART discontinuations, overall and for pretreatment CD4 cell count categories (<or=200, 201-350, 351-500, and >500 cells/microl). RESULTS: Median CD4 cell count increased from 270 cells/microl pre-ART to an estimated 556 cells/microl at 3 and 532 cells/microl at 7 years after starting ART in analyses ignoring treatment discontinuations, and to 570 and 640 cells/microl, respectively, had all patients continued ART. However, even had ART been continued, an estimated 25, 9, 3, and 2% of patients with pretreatment CD4 cell counts of 200 or less, 201-350, 351-500, and more than 500 cells/microl would have had CD4 cell counts of 350 cells/microl or less after 7 years. CONCLUSION: If patients remain on ART, CD4 cell counts increase in most patients for at least 7 years. However, the substantial percentage of patients starting therapy at low CD4 cell counts who still had low CD4 cell counts after 7 years provides support for ART initiation at higher CD4 cell counts.
Authors: Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson Journal: HIV Clin Trials Date: 2008 Jul-Aug
Authors: Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton Journal: AIDS Date: 2008-04-23 Impact factor: 4.177
Authors: Felipe García; Elisa de Lazzari; Montserrat Plana; Pedro Castro; Gabriel Mestre; Meritxell Nomdedeu; Emilio Fumero; Esteban Martínez; Josep Mallolas; José L Blanco; José M Miró; Tomás Pumarola; Teresa Gallart; José M Gatell Journal: J Acquir Immune Defic Syndr Date: 2004-06-01 Impact factor: 3.731
Authors: Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: AIDS Date: 2008-10-18 Impact factor: 4.632
Authors: S Krishnan; K Wu; M Smurzynski; R J Bosch; C A Benson; A C Collier; M K Klebert; J Feinberg; S L Koletar Journal: HIV Clin Trials Date: 2011 Jul-Aug
Authors: James H McMahon; Christine A Wanke; Julian H Elliott; Sally Skinner; Alice M Tang Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Alan R Lifson; Elizabeth M Krantz; Lynn E Eberly; Matthew J Dolan; Vincent C Marconi; Amy C Weintrob; Nancy F Crum-Cianflone; Anuradha Ganesan; Patricia L Grambsch; Brian K Agan Journal: AIDS Res Ther Date: 2011-01-18 Impact factor: 2.250
Authors: Gregory K Robbins; William Lester; Kristin L Johnson; Yuchiao Chang; Gregory Estey; Dominic Surrao; Kimon Zachary; Sara M Lammert; Henry C Chueh; James B Meigs; Kenneth A Freedberg Journal: Ann Intern Med Date: 2012-12-04 Impact factor: 25.391
Authors: Marlene Smurzynski; Kunling Wu; Jeffrey T Schouten; Judith J Lok; Ronald J Bosch; Babafemi Taiwo; Victoria Anne Johnson; Ann C Collier Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Jeffrey A Boatman; Jason V Baker; Sean Emery; Hansjakob Furrer; David M Mushatt; Dalibor Sedláček; Jens D Lundgren; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731